- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 ; volume:21 ; number:1 ; day:18 ; month:4 ; year:2023 ; pages:1-14 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (18.4.2023), 1-14, 12.2023
- Urheber
-
Ascierto, Paolo A.
Blank, Christian
Eggermont, Alexander M.
Garbe, Claus
Gershenwald, Jeffrey E.
Hamid, Omid
Hauschild, Axel
Luke, Jason J.
Mehnert, Janice M.
Sosman, Jeffrey A.
Tawbi, Hussein A.
Mandalà, Mario
Testori, Alessandro
Caracò, Corrado
Osman, Iman
Puzanov, Igor
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04100-y
- URN
-
urn:nbn:de:101:1-2023082921313108576351
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ascierto, Paolo A.
- Blank, Christian
- Eggermont, Alexander M.
- Garbe, Claus
- Gershenwald, Jeffrey E.
- Hamid, Omid
- Hauschild, Axel
- Luke, Jason J.
- Mehnert, Janice M.
- Sosman, Jeffrey A.
- Tawbi, Hussein A.
- Mandalà, Mario
- Testori, Alessandro
- Caracò, Corrado
- Osman, Iman
- Puzanov, Igor
- SpringerLink (Online service)
Ähnliche Objekte (12)
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application